Blueprint Medicines Announces Proof-of-Concept Data from Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors
"The clinical activity observed to date in the dose escalation portion of this Phase 1 study is promising," said
"These data help to validate
Data from the Ongoing Phase 1 Clinical Trial
BLU-285 is currently being evaluated in the dose escalation stage of a Phase 1 clinical trial in patients with unresectable PDGFRα-driven GIST and patients with treatment-resistant KIT-driven GIST. As of the data cutoff date of
Preliminary pharmacokinetic analysis demonstrated relatively rapid absorption of BLU-285 and a mean half-life of over 24 hours that supports once daily dosing.
Preliminary Safety Data
As of the data cutoff date of
Preliminary Clinical Activity Data
As of the data cutoff date of
- In PDGFRα-driven GIST, investigators observed radiographic tumor reduction in 14 of 15 evaluable patients with six patients achieving a partial response (PR) by RECIST (five confirmed, one unconfirmed). Tumor reduction was observed at the first dose level in the PDGFRα-driven subgroup of advanced GIST.
- In KIT-driven GIST, investigators observed radiographic tumor reduction in five of the 13 evaluable patients, including one who achieved a PR by RECIST (confirmed). At the higher dose levels (greater than or equal to 135 mg), four out of six patients had tumor reduction, including the patient with a PR, suggesting increased clinical activity with increased dose. Tumor shrinkage was first observed at the fourth dose level in the KIT-driven subgroup of advanced GIST.
- Among all 36 patients treated, 27 patients remained on BLU-285, including all 18 patients with PDGFRα-driven GIST, with a duration of treatment ranging from 0.8 months to 12.3 months.
- Nine patients discontinued treatment with BLU-285 due to progressive disease.
Clinical Development Plans for BLU-285 in GIST
Based on the favorable safety profile and encouraging clinical activity observed to date in the Phase 1 clinical trial for BLU-285 for the treatment of advanced GIST,
Conference Call Information
To participate in the conference call, please dial 1-855-728-4793 (domestic) or 1-503-343-6666 (international) and refer to conference ID 10770449. A live webcast of the presentation will also be available under "Events and Presentations" in the Investors section of
About the Phase 1 Clinical Trial for BLU-285 for PDGFRα-Driven and KIT-Driven GIST
GIST is the most common sarcoma, or tumor of bone or connective tissue, of the gastrointestinal (GI) tract. Tumors arise from cells in the wall of the GI tract and occur most often in the stomach or small intestine. Most patients are diagnosed between the ages of 50-80, and diagnosis is typically triggered by GI bleeding, incidental findings during surgery or imaging and, in rare cases, tumor rupture or GI obstruction. Approximately 80 percent of GIST patients have KIT-driven GIST, and
BLU-285 is an orally available, potent and highly selective inhibitor of D842V mutant PDGFRα and Exon 17 mutant KIT.
Blueprint Medicines is developing a new generation of targeted kinase medicines to improve the lives of patients with genomically defined diseases. Its approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Blueprint Medicines is advancing three programs in clinical development for subsets of patients with gastrointestinal stromal tumors, hepatocellular carcinoma and systemic mastocytosis, as well as multiple programs in research and preclinical development.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding plans and timelines for the clinical development of BLU-285; our ability to implement our clinical development plans for BLU-285 for the treatment of advanced GIST; our ability to enroll patients in our ongoing Phase 1 clinical trial for BLU-285 in advanced GIST; and
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/blueprint-medicines-announces-proof-of-concept-data-from-phase-1-clinical-trial-of-blu-285-in-patients-with-advanced-gastrointestinal-stromal-tumors-300370923.html
Investor Relations: Kristin Williams, Blueprint Medicines Corporation, 617-714-6674, email@example.com ; Media Relations: Rachel Hutman, W2O Group, 301-801-5540, firstname.lastname@example.org